| Stereochemistry | ACHIRAL |
| Molecular Formula | C14H16N2.ClH |
| Molecular Weight | 248.751 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CN\C(CC1=CC=C2C=CC=CC2=C1)=N/C
InChI
InChIKey=WEDBCIMSKMMRAG-UHFFFAOYSA-N
InChI=1S/C14H16N2.ClH/c1-15-14(16-2)10-11-7-8-12-5-3-4-6-13(12)9-11;/h3-9H,10H2,1-2H3,(H,15,16);1H
| Molecular Formula | C14H16N2 |
| Molecular Weight | 212.2902 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Optical Activity | NONE |
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Napactadine is a bicyclic antidepressant agent. It is a histamine-H1 receptor antagonist. Preliminary results indicated a marked
improvement in depressive symptomalology within 7 days
of treatment, as measured by the Hamilton depression
scale. However, clinical studies were discontinued after chronic administration of napactadine because an
elevation in liver enzyme levels was observed in some
patients.
